202 related articles for article (PubMed ID: 30109501)
21. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yu YH; Liang H; Liu GY; Xiang YQ; Guo X; Lv X
Oral Oncol; 2017 Jul; 70():7-13. PubMed ID: 28622892
[TBL] [Abstract][Full Text] [Related]
23. Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer.
Melotek JM; Cooper BT; Koshy M; Silverman JS; Spiotto MT
J Otolaryngol Head Neck Surg; 2016 Nov; 45(1):62. PubMed ID: 27881143
[TBL] [Abstract][Full Text] [Related]
24. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H
BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
Golden DW; Rudra S; Witt ME; Nwizu T; Cohen EE; Blair E; Stenson KM; Vokes EE; Haraf DJ
Oral Oncol; 2013 Mar; 49(3):277-82. PubMed ID: 23102863
[TBL] [Abstract][Full Text] [Related]
26. Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis.
Lee YY; Park W; Huh SJ; Yoon A; Park JY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
Anticancer Res; 2013 Oct; 33(10):4675-81. PubMed ID: 24123048
[TBL] [Abstract][Full Text] [Related]
27. Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta, Indonesia: A hospital-based retrospective study.
Hutajulu SH; Howdon D; Taroeno-Hariadi KW; Hardianti MS; Purwanto I; Indrasari SR; Herdini C; Hariwiyanto B; Ghozali A; Kusumo H; Dhamiyati W; Dwidanarti SR; Tan IB; Kurnianda J; Allsop MJ
PLoS One; 2021; 16(2):e0246638. PubMed ID: 33577563
[TBL] [Abstract][Full Text] [Related]
28. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma : A matched-pair multicenter analysis of outcomes.
Dong YY; Xiang C; Lu JX; Su YX; Pan YF; Cai R; Zhang RJ; He ZK; Liu ML; Huang H; Bai X; Tang HY; Shi YH; Wang Y; Jiang W
Strahlenther Onkol; 2016 Jun; 192(6):394-402. PubMed ID: 27215563
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
Wang D; Zhou J; Zheng J; Zhang J; Chen Y; Li W; Wang R
Cancer Biomark; 2018; 21(4):875-881. PubMed ID: 29439312
[TBL] [Abstract][Full Text] [Related]
30. Outcomes in nasopharyngeal carcinoma: Results from a nonendemic cohort.
Laskar SG; Gurram L; Gupta T; Budrukkar A; Murthy V; Agarwal JP
Indian J Cancer; 2016; 53(4):493-498. PubMed ID: 28485337
[TBL] [Abstract][Full Text] [Related]
31. The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy.
Peng H; Chen L; Li WF; Guo R; Mao YP; Zhang Y; Zhang F; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
Sci Rep; 2016 Apr; 6():24332. PubMed ID: 27071833
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy in local-regionally advanced nasopharyngeal carcinoma: A National Cancer Database analysis.
Tam M; Lee A; Wu SP; Gerber NK; Li Z; Givi B; Hu K; Schreiber D
Laryngoscope; 2018 Dec; 128(12):2770-2777. PubMed ID: 30133799
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety.
Wee J; Tan EH; Tai BC; Wong HB; Leong SS; Tan T; Chua ET; Yang E; Lee KM; Fong KW; Tan HS; Lee KS; Loong S; Sethi V; Chua EJ; Machin D
J Clin Oncol; 2005 Sep; 23(27):6730-8. PubMed ID: 16170180
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcome and morbidity in pediatric patients with nasopharyngeal cancer treated with chemoradiotherapy.
Sahai P; Mohanti BK; Sharma A; Thakar A; Bhasker S; Kakkar A; Sharma MC; Upadhyay AD
Pediatr Blood Cancer; 2017 Feb; 64(2):259-266. PubMed ID: 27681956
[TBL] [Abstract][Full Text] [Related]
36. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
[TBL] [Abstract][Full Text] [Related]
37. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis.
Liao W; Huang J; Wu Q; Zhu G; Wang X; Wen F; Zhang P; Zhang N; Li Q
Oral Oncol; 2019 Jun; 93():15-20. PubMed ID: 31109691
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and feasibility of cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma.
Demizu Y; Sasaki R; Soejima T; Maruta T; Okamoto Y; Yamada K; Yoden E; Ejima Y; Ota Y; Ishida H; Nibu K; Sugimura K
Jpn J Clin Oncol; 2006 Oct; 36(10):620-5. PubMed ID: 16905756
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Effect of Chemotherapy Cycle in Nasopharyngeal Carcinoma (NPC) Patients Who Developed Bone-Only Metastasis.
Nong S; Pan X; Chen K; Li Y; Zhu X
Med Sci Monit; 2020 Jun; 26():e922244. PubMed ID: 32541642
[TBL] [Abstract][Full Text] [Related]
40. Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A propensity score analysis.
Xia WX; Liang H; Lv X; Wang L; Qian CN; Ye YF; Ke LR; Qiu WZ; Yu YH; Huang XJ; Liu GY; Zhao C; Xiang YQ; Guo X
Oral Oncol; 2017 Apr; 67():167-174. PubMed ID: 28351572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
